We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Results 1 to 5 of 5
Most popular |Most recent


Recent Decision Casts Doubt on the Fate of Tribal Sovereign Immunity at the PTAB

USA - January 9 2018 The topic of sovereign immunity was raised a number of times in inter partes review (IPR) proceedings in 2017, and it was cast into the national...


Amgen Files Petition for Rehearing En Banc of Praluent Written Description and Enablement Issues

USA - December 27 2017 In October, a Federal Circuit panel vacated a permanent injunction against Sanofi and Regeneron’s Praluent and remanded the proceeding to the...


New Report Says Biosimilars Could Save $54 Billion in Biologics Spending

USA - November 7 2017 According to a new report by RAND Corporation, biosimilars could save $54 billion in healthcare spending on biologics over the next ten years...


Federal Judge and U.S. Senators Weigh in as PTAB Considers Tribal Sovereign Immunity Defense in IPR Proceeding

USA - October 16 2017 Senior U.S. Circuit Judge William Bryson ruled on Monday that all the asserted claims in the six Restasis patents that Allergan PLC ("Allergan")...


Tribal Sovereign Immunity: the New Defense Against IPR’s?

USA - September 27 2017 Just recently, Allergan PLC (“Allergan”) announced that it had transferred the patents for its dry-eye drug Restasis to the Saint Regis Mohawk Tribe...